In Vitro and in Vivo Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics With Low Abuse Potential

Frontiers in Psychiatry - Switzerland
doi 10.3389/fpsyt.2017.00052
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Abuse-Deterrent Formulations, an Evolving Technology Against the Abuse and Misuse of Opioid Analgesics

Journal of Medical Toxicology
MutagenesisToxicologyHealth
2012English

Association Statistics Under the PPL Framework

English

Side-Effects of Mixed Agonist-Antagonist Analgesics Used in Sequential Anaesthesia.

British Journal of Clinical Pharmacology
Pharmacology
1979English

Cebranopadol, a Mixed Opioid Agonist, Reduces Cocaine Self-Administration Through Nociceptin Opioid and Mu Opioid Receptors

Frontiers in Psychiatry
PsychiatryMental Health
2017English

Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States

PLoS ONE
Multidisciplinary
2016English

Project of Sanitary Safe-Guarding of “Piccole Produzioni Locali” (Ppl)

Italian Journal of Food Safety
Food Science
2010English

Kurikulum Praktik Profesi Lapangan (Ppl) Jurusan Tarbiyah Stain Kudus

ThufuLA: Jurnal Inovasi Pendidikan Guru Raudhatul Athfal
2014English

N-Acetylaspartylglutamate Is an Agonist at mGluR3 in Vivo and in Vitro

Journal of Neurochemistry
BiochemistryMolecular NeuroscienceCellular
2011English

Use of in Vivo Apparent pA2 Analysis in Assessment of Opioid Abuse Liability

Trends in Pharmacological Sciences
ToxicologyPharmacology
1992English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy